drugset
drugset / Trial / NCT04626921

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

NCT04626921 ↗

Phase 2/3 Completed 55 enrolled Clene Nanomedicine George Clinical · collab
NaSingle-groupOpen-labelTreatment

Summary

Open-label, long-term extension study available to participants who have completed CNMAu8.201.

Timeline

Start
2020-10-22
Primary completion
2023-05-29
Completion
2023-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CNM-Au8 Other / unclassified 30 mg —

Indications

multiple sclerosis